Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients

• Status: Completed
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the effect of adding fish oil to Fingolimod on some serum cytokines in patients with Relapsing-Remitting Multiple Sclerosis.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Isfahan University of Medical Sciences
• Collaborator: Shiraz University of Medical Sciences
• Treatments: Fingolimod Hydrochloride

Criteria

Inclusion Criteria:

• Patients with relapsing-remitting multiple sclerosis according to McDonald's criteria (2010)

• Age between 18 and 45 years

• Expanded Disability Status Scale (EDSS) between 0-5

• History of at least one relapse during the last year

• Intolerance or serious complications when receiving interferons

• Not receiving interferons in the last two months

• Not having relapse in the last 30 days

• Negative pregnancy test

• History of varicella or varicella vaccination, or positive test for anti-varicella antibodies

• Not to take any medication or dietary complement without permission of the physician

• Filling informed consent

Exclusion Criteria:

• Having chronic and infectious diseases

• History of cardiovascular diseases

• Taking corticosteroids in the last 30 days

• Taking chemotherapy agents such as Cyclophosphamide

• Patients who have taken fingolimod before

• Patients who experience relapse during the study